World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia (Q33223628)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia (English)

1 reference

Europe PubMed Central

24 July 2017

0 references

0 references

biological psychiatry

1 reference

based on heuristic

inferred from title

Birte Yding Glenthøj

4

object named as

Birte Glenthoj

1 reference

Europe PubMed Central

24 July 2017

object named as

Peter Falkai

1

0 references

Hans-Jürgen Möller

6

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

24 July 2017

Jeffrey Lieberman

3

object named as

Jeffrey Lieberman

1 reference

Europe PubMed Central

24 July 2017

Wagner Farid Gattaz

5

object named as

Wagner F Gattaz

1 reference

Europe PubMed Central

24 July 2017

author name string

Thomas Wobrock

2

1 reference

Europe PubMed Central

24 July 2017

WFSBP Task Force on Treatment Guidelines for Schizophrenia

7

1 reference

Europe PubMed Central

24 July 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

24 July 2017

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

24 July 2017

6

1 reference

Europe PubMed Central

24 July 2017

132-191

1 reference

Europe PubMed Central

24 July 2017

3

1 reference

Europe PubMed Central

24 July 2017

Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Predictors of acute dystonia in first-episode psychotic patients.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

What Clinicians Should Know About the QT Interval

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The impact of weight gain on quality of life among persons with schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Intramuscular preparations of antipsychotics: uses and relevance in clinical practice

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Negative v positive schizophrenia. Definition and validation.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Managing acute exacerbations of schizophrenia: focus on quetiapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Motivational interviewing among psychiatric in-patients with substance use disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The impact of cognitive remediation on psychiatric symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The prediction of criminal and violent recidivism among mentally disordered offenders: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacological management of first-episode schizophrenia and related nonaffective psychoses

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Defining treatment refractoriness in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Causes of the excess mortality of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine: efficacy and safety

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Structural evaluation of the prefrontal cortex in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Treatment of the psychotic patient who is violent

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Catatonia. II. Treatment with lorazepam and electroconvulsive therapy.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Treatment of negative symptoms

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Gender differences in schizophrenia: hormonal effect or subtypes?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Quetiapine. A review of its use in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Optimal dosing of atypical antipsychotics in adults: a review of the current evidence

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Family support and substance use outcomes for persons with mental illness and substance use disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Evaluation of treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The two-syndrome concept: origins and current status

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Sexual dysfunction and antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Side effects of electroconvulsive therapy

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The varied outcomes of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Overview: maintenance therapy in psychiatry: I. Schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Dose response and dose equivalence of antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine-related seizures

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Conventional antipsychotic medications for schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Electroconvulsive therapy and memory loss: a personal journey

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Psychosocial approaches to dual diagnosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clinical potential of omega-3 fatty acids in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine eligibility among state hospital patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Significant interaction between clozapine and cocaine in cocaine addicts

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Prognostic scale for chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Convulsive therapy in schizophrenia?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Patterns of current and lifetime substance use in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Interventions to reduce the stigma associated with severe mental illness: experiences from the open the doors program in Germany.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine maintenance therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neuroleptic reduction of cocaine-induced paranoia but not euphoria?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Physical and sexual assault history in women with serious mental illness: prevalence, correlates, treatment, and future research directions

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

[Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics]

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Somatic treatment of catatonia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Acute and long-term treatment of catatonia with risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effectiveness of ECT combined with risperidone against aggression in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Treatment of late-life schizophrenia with neuroleptics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Medical comorbidity in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Psychopharmacologic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Citalopram augmentation of antipsychotic treatment in older schizophrenia patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Myocarditis and cardiomyopathy associated with clozapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Dose response and atypical antipsychotics in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Prolactin levels and adverse events in patients treated with risperidone.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Substance use disorder and the early course of illness in schizophrenia and affective psychosis.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Costs of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined electroconvulsive and neuroleptic therapy in schizophrenia refractory to neuroleptics.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Elevated clozapine plasma level with lamotrigine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined electroconvulsive-clozapine therapy.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Myocarditis and cardiomyopathy associated with clozapine use in the United States

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

"Catatonic dilemma". Therapy with lorazepam and clozapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Sex differences in schizophrenia, a review of the literature

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine treatment for patients with schizophrenia and substance abuse

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The Mount Sinai conference on the pharmacotherapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Physical health monitoring of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Subtype progression and pathophysiologic deterioration in early schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Early detection and intervention with schizophrenia: rationale

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Review: treatment of schizophrenia. State of the art.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Management of the negative symptoms of schizophrenia: new treatment options

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Novel antipsychotics in the long-term treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Non-neuroleptic approaches to treating negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Disulfiram treatment for alcoholism in severe mental illness

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Six-month outcomes for patients who switched to olanzapine treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacotherapy for schizophrenia and co-occurring substance use disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Tardive dyskinesia in psychiatric patients with substance use disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Determining the optimal dose of haloperidol in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Short-term inpatient pharmacotherapy of schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neuroleptic malignant syndrome: a review

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Concomitant clozapine reduces smoking in patients treated with risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Subjective memory complaints: a review of patient self-assessment of memory after electroconvulsive therapy

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Acute dystonia induced by neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Lamotrigine--clozapine combination in refractory schizophrenia: three cases

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Chemical brain anatomy in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clinical guidelines: developing guidelines

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The onset and time course of response of negative symptoms to add-on fluvoxamine treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacological treatment of substance-abusing schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antidepressant for substance-abusing schizophrenic patients: a minireview

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Suicide and schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Prevalence of alcohol and drug abuse in schizophrenic inpatients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Metabolic drug interactions with new psychotropic agents.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An open trial of risperidone augmentation of partial response to clozapine.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Safety of quetiapine during pregnancy

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Quetiapine and pregnancy

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Benzodiazepines and the psychopathology of catatonia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Response of catatonia to risperidone: two case reports.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Does cognitive function improve with quetiapine in comparison to haloperidol?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

High-dose treatment with haloperidol: the effect of dose reduction.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Practitioner review: electroconvulsive therapy in adolescents

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

GABA and Schizophrenia: A Review of Basic Science and Clinical Studies

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

[Psychotherapy of positive symptoms in the treatment of patients with schizophrenia psychosis]

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacotherapy of schizophrenia patients with comorbid substance abuse.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Benzodiazepines in the treatment of schizophrenia: a review and reappraisal

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Consistency of atypical antipsychotic superiority to placebo in recent clinical trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Propranolol as an adjunct to the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Relationship of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Establishing the onset of psychotic illness.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined treatment of schizophrenic psychoses with haloperidol and valproate

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Half a century of ECT use in young people

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Sex and Schizophrenia: Effects of Diagnostic Stringency, and Associations with Premorbid Variables

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone and clozapine combination for the treatment of refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Fluoxetine as an Adjunct to Conventional Antipsychotic Treatment of Schizophrenia Patients with Residual Symptoms

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The Influence of Age and Sex on the Onset and Early Course of Schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Identifiers

10.1080/15622970510030090

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33223628&oldid=1977237990"